...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Additional Reports Of Exempt Distribution.

One more Promissory Note: Dated 2024-06-27 for $ 274,077.00

With 275K warrants @ $1.03 expire, 2029-06-27

Out of Alberta.

 

Koo

 

Share
New Message
Please login to post a reply